Opinion|Videos|December 3, 2024
Evaluating Cough Relief With Oral Nalbuphine in Patients With IPF
Author(s)Steven D. Nathan, MD
Key Takeaways
- The study focused on assessing oral nalbuphine extended release for cough relief in idiopathic pulmonary fibrosis patients.
- A randomized, double-blind, placebo-controlled trial design was employed to ensure robust and unbiased results.
Steven Nathan, MD, discusses the abstract “Analysis of Relief-of-Cough in Patients With Idiopathic Pulmonary Fibrosis Treated With Oral Nalbuphine Extended Release,” which aimed to assess the effectiveness of oral nalbuphine extended release in providing relief from chronic cough in patients with IPF; the study used a clinical trial design to evaluate cough severity, with results showing that nalbuphine significantly reduced cough frequency and intensity, offering a potential new treatment option for managing this common and debilitating symptom of IPF.
Advertisement
Episodes in this series
- Briefly describe the abstract “Analysis of Relief-of-Cough in Patients With Idiopathic Pulmonary Fibrosis Treated With Oral Nalbuphine Extended Release.”
- What was the objective of this study?
- How was this study designed/what methodology was used?
- What results were presented?
Advertisement
Related to this article
A higher PNR is associated with lower odds of MASLD and advanced liver fibrosis, but further studies are needed to validate findings.
Speakers at CHEST 2026 walked through the first CHEST guideline for non-CF adult bronchiectasis, including which preventive therapy to start first.
On the opening day of CHEST 2026, the organization's flagship journal highlights a trio of key papers with practice-changing results for COPD.
Selected presentations from “Reframing COPD: Phenotypes, Outcomes, Therapeutics, and the Future of Care Delivery,” a session on the opening day of CHEST 2026.
Non-Hodgkin lymphoma mortality trends impact lower-income, less-educated communities, highlighting health disparities and needs for health equity.
Older patients with obstructive sleep apnea (OSA) had more cardiometabolic disease and poorer reported sleep quality than younger patients.
SaTScan detects an acute HCV outbreak cluster in California, showing the potential of automated surveillance, though real-time testing is needed.
The editor in chief of Evidence-Based Oncology, who was recently named medical director of Precision Medicine for The US Oncology Network, discussed milestones met and those still to be achieved.
Advertisement
Advertisement
Trending on AJMC
1
Pathological Response Does Not Reliably Predict Survival in Sarcoma
2
5 Things to Know About the One Big Beautiful Bill Act
3
New CHEST Guidelines Offer a Road Map for Bronchiectasis
4
Coroner Reports Pennsylvania's Sixth Measles-Associated Death
5